Skip to main content

Table 2 Clinical characteristics of subjects

From: Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo

Variables Whole group HAART subjects ART naive subjects p
  n = 235 n = 179 n = 56  
Known HIV infection duration (years) 4,7 ± 3,2 5,3 ± 3,04 2,8 ± 2,9 <0,0001
Duration of HAART (months) NA 46,2 ± 30,08 NA  
WHO stage for HIV clinical disease:     
- Stage 1 25 (10,6) 12 (5,1) 13 (5,5) 0,39
- Stage 2 53 (22,6) 21 (8,9) 32 (13,6) 0,93
- Stage 3 140 (59,6) 129 (54,9) 11 (4,7) 0,0039
- Stage 4 17 (7,2) 17 (7,2) 0 <0,0001
Body mass index (kg/m2) 22,3 ± 3,8 22,5 ± 3,9 21,7 ± 3,4 0,198
SBP (mmHg) 118,82 ± 20,89 120,58 ± 21,7 113,2 ± 16,7 0,023
DBP (mmHg) 77,7 ± 14,02 79,8 ± 14,7 71,8 ± 11,6 0,0002
HAART regimen:     
AZT + 3TC + NVP NA 164 (94,8) NA  
d4T + 3TC + NVP NA 3 (1,6) NA  
ABC + DDI + Lp/r NA 9 (5) NA  
TDF + 3TC + EFV NA 3 (1,6) NA  
  1. HTA = hypertension; BMC = body mass index; SBP = Systolic blood pressure; DBP = diastolic blood pressure; CKD = chronic kidney disease; HAART: Highly active antiretroviral therapy. NA: not applicable; d4T: stavudine, 3TC: lamivudine, NVP: nevirapine, ABC: abacavir, DDI: didanosine, Lp/r : lopinavir/ritonavir, EFV: efavirenz, TDF: tenofovir.